Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis
International Journal of Molecular Sciences · 24.02.2025 · 26 (5) · 1943
DOI: 10.3390/ijms26051943 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.02.2025. Verfasst von Federica Malighetti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Antigens, Neoplasm, LIM Domain Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, AIRC-.
Abstract (Originalsprache)
Breast cancer (BC) is a highly heterogeneous disease with diverse molecular subtypes, which complicates prognosis and treatment. In this study, we performed a multi-omics clustering analysis using the Cancer Integration via MultIkernel LeaRning (CIMLR) method on a large BC dataset from The Cancer Genome Atlas (TCGA) to identify key prognostic biomarkers. We identified three genes—LMO1, PRAME, and RSPO2—that were significantly associated with poor prognosis in both the TCGA dataset and an additional dataset comprising 146 metastatic BC patients. Patients’ stratification based on the expression of these three genes revealed distinct subtypes with markedly different overall survival (OS) outcomes. Further validation using almost 2000 BC patients’ data from the METABRIC dataset and RNA sequencing data from therapy-resistant cell lines confirmed the upregulation of LMO1 and PRAME, respectively, in patients with worse prognosis and in resistant cells, also suggesting their potential role in drug resistance. Our findings highlight LMO1 and PRAME as potential biomarkers for identifying high-risk BC patients and informing targeted treatment strategies. This study provides valuable insights into the multi-omics landscape of BC and underscores the importance of personalized therapeutic approaches based on molecular profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
- Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
- Phase 1 Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
ORCID-Profile: Federica Malighetti, Matteo Villa, Alberto Maria Villa, Sara Pelucchi, Andrea Aroldi, Diego Luigi Cortinovis, Stefania Canova, Luca Mologni, Daniele Ramazzotti, Nicoletta Cordani
Förderung
- Italian Association for Cancer Research
- AIRC-
Zitieren
APA
Malighetti, F., Villa, M., Villa, A. M., Pelucchi, S., Aroldi, A., Cortinovis, D. L., Canova, S., Capici, S., Cazzaniga, M. E., Mologni, L., Ramazzotti, D., & Cordani, N. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. International Journal of Molecular Sciences, 26(5), 1943. https://doi.org/10.3390/ijms26051943
Vancouver
Malighetti F, Villa M, Villa AM, Pelucchi S, Aroldi A, Cortinovis DL, et al. Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. International Journal of Molecular Sciences. 2025;26(5):1943. doi:10.3390/ijms26051943
BibTeX
@article{Malighetti2025,
author = {Malighetti, Federica and Villa, Matteo and Villa, Alberto Maria and Pelucchi, Sara and Aroldi, Andrea and Cortinovis, Diego Luigi and Canova, Stefania and Capici, Serena and Cazzaniga, Marina Elena and Mologni, Luca and Ramazzotti, Daniele and Cordani, Nicoletta},
title = {Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {5},
pages = {1943},
doi = {10.3390/ijms26051943}
}
EUVIMED